ProCE Banner Activity

NRG1 Oncogenic Gene Fusions Across Solid Tumors: Emerging New Agents for an Important Target

Clinical Thought
Expert commentary by Joshua Sabari, MD, on the role of NRG1 fusions in solid tumors and the emerging targeted therapies for patients harboring this oncogenic alteration.

Released: February 28, 2022

Expiration: February 27, 2023

Share

Faculty

Joshua Sabari

Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
Phase I Experimental Therapeutics
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Elevation Oncology

Partners

American Society for Clinical Pathology

ProCE Banner

Faculty Disclosure

Primary Author

Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
Phase I Experimental Therapeutics
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Joshua Sabari, MD, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca, Genentech, Janssen, Regeneron, Pfizer, Sanofi Genzyme and Takeda.